top of page
  • Completed

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

Updated: May 26, 2022

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)


MEDI2228

The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory


Sponsor

MedImmune LLC


Multiple Locations

International Study

 

Official Title: A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

First Posted: April 5, 2018


https://clinicaltrials.gov/ct2/show/NCT03489525

 

Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)

Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

 

Anti-BCMA ADC MEDI2228

Anti-BCMA/PBD ADC MEDI2228 (Code C150127)

ADC MEDI2228

Anti-BCMA ADC MEDI2228

Anti-BCMA/PBD ADC MEDI2228

Anti-BCMA/PBD MEDI2228

Antibody-drug Conjugate MEDI2228

MEDI 2228

MEDI-2228

MEDI2228

 

Locations

United States, Arizona

United States, Florida

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, North Carolina

United States, Virginia

Australia

Europe

Spain

Greece






Posts Archive
bottom of page